insights_auto
Why is NVAX up 2.69%?
Dive Deeperchevron_right
NVAX:NASDAQ
Novavax Inc
$11.62
arrow_upward
+2.69%(+0.31) 1D
Oct 7, 11:35:41 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$11.01
High
$11.75
Low
$10.90
Mkt. cap
1.91B
Avg. vol.
6.63M
Volume
3.33M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
Open
$11.01
High
$11.75
Low
$10.90
Mkt. cap
1.91B
Avg. vol.
6.63M
Volume
3.33M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
Benzinga
·
4 hours ago
Transcript: Novavax Q2 2026 Earnings Conference Call
Yahoo Finance
·
5 hours ago
Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility
Investing.com
·
6 hours ago
Novavax and Moderna shares fall after plague concerns ease, Citi comments
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com